{"pmid":32497168,"title":"On setting expectations for a SARS-CoV-2 Vaccine.","text":["On setting expectations for a SARS-CoV-2 Vaccine.","The global coronavirus pandemic is unlike any other since 1918. A century of dramatic medical advances has produced a public expectation that the medical field will rapidly provide solutions to restore normalcy. In under 6 months, since SARS-CoV-2 was identified, the massive international effort to develop a SARS-CoV-2 vaccine has generated more than 140 vaccines in different stages of development with 9 already recruiting into clinical trials posted on clinicaltrials.gov. The long-term strategy to handle COVID-19 will almost certainly rely on vaccines. But, what type of protection can we realistically expect to achieve from vaccines and when?","Clin Infect Dis","Canaday, David H","Gravenstein, Stefan","32497168"],"abstract":["The global coronavirus pandemic is unlike any other since 1918. A century of dramatic medical advances has produced a public expectation that the medical field will rapidly provide solutions to restore normalcy. In under 6 months, since SARS-CoV-2 was identified, the massive international effort to develop a SARS-CoV-2 vaccine has generated more than 140 vaccines in different stages of development with 9 already recruiting into clinical trials posted on clinicaltrials.gov. The long-term strategy to handle COVID-19 will almost certainly rely on vaccines. But, what type of protection can we realistically expect to achieve from vaccines and when?"],"journal":"Clin Infect Dis","authors":["Canaday, David H","Gravenstein, Stefan"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32497168","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1093/cid/ciaa726","keywords":["covid-19","sars-cov-2","t cells","vaccine"],"topics":["Treatment"],"weight":1,"_version_":1668712823858921472,"score":9.490897,"similar":[{"pmid":32399192,"pmcid":"PMC7194468","title":"Recent advances in influenza vaccines.","text":["Recent advances in influenza vaccines.","Seasonal influenza remains a major public health problem, responsible for hundreds of thousands of deaths every year, mostly of elderly people. Despite the wide availability of vaccines, there are multiple problems decreasing the effectiveness of vaccination programs. These include viral variability and hence the requirement to match strains by estimating which will become prevalent each season, problems associated with vaccine and adjuvant production, and the route of administration as well as the perceived lower vaccine efficiency in older adults. Clinical protection is still suboptimal for all of these reasons, and vaccine uptake remains too low in most countries. Efforts to improve the effectiveness of influenza vaccines include developing universal vaccines independent of the circulating strains in any particular season and stimulating cellular as well as humoral responses, especially in the elderly. This commentary assesses progress over the last 3 years towards achieving these aims. Since the beginning of 2020, an unprecedented international academic and industrial effort to develop effective vaccines against the new coronavirus SARS-CoV-2 has diverted attention away from influenza, but many of the lessons learned for the one will synergize with the other to mutual advantage. And, unlike the SARS-1 epidemic and, we hope, the SARS-CoV-2 pandemic, influenza will not be eliminated and thus efforts to improve influenza vaccines will remain of crucial importance.","F1000Res","Pawelec, Graham","McElhaney, Janet","32399192"],"abstract":["Seasonal influenza remains a major public health problem, responsible for hundreds of thousands of deaths every year, mostly of elderly people. Despite the wide availability of vaccines, there are multiple problems decreasing the effectiveness of vaccination programs. These include viral variability and hence the requirement to match strains by estimating which will become prevalent each season, problems associated with vaccine and adjuvant production, and the route of administration as well as the perceived lower vaccine efficiency in older adults. Clinical protection is still suboptimal for all of these reasons, and vaccine uptake remains too low in most countries. Efforts to improve the effectiveness of influenza vaccines include developing universal vaccines independent of the circulating strains in any particular season and stimulating cellular as well as humoral responses, especially in the elderly. This commentary assesses progress over the last 3 years towards achieving these aims. Since the beginning of 2020, an unprecedented international academic and industrial effort to develop effective vaccines against the new coronavirus SARS-CoV-2 has diverted attention away from influenza, but many of the lessons learned for the one will synergize with the other to mutual advantage. And, unlike the SARS-1 epidemic and, we hope, the SARS-CoV-2 pandemic, influenza will not be eliminated and thus efforts to improve influenza vaccines will remain of crucial importance."],"journal":"F1000Res","authors":["Pawelec, Graham","McElhaney, Janet"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399192","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.12688/f1000research.22611.1","keywords":["adjuvant","effectiveness","elderly","influenza","vaccine"],"topics":["Treatment"],"weight":1,"_version_":1666714494960664576,"score":178.16232},{"pmid":32235387,"title":"Progress and Prospects on Vaccine Development against SARS-CoV-2.","text":["Progress and Prospects on Vaccine Development against SARS-CoV-2.","In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2.","Vaccines (Basel)","Zhang, Jinyong","Zeng, Hao","Gu, Jiang","Li, Haibo","Zheng, Lixin","Zou, Quanming","32235387"],"abstract":["In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2."],"journal":"Vaccines (Basel)","authors":["Zhang, Jinyong","Zeng, Hao","Gu, Jiang","Li, Haibo","Zheng, Lixin","Zou, Quanming"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32235387","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.3390/vaccines8020153","keywords":["sars-cov-2","adjuvant","animal model","vaccine"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138490281132032,"score":161.05214},{"pmid":32234130,"title":"[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].","text":["[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].","The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same beta-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated.","Zhonghua Yu Fang Yi Xue Za Zhi","Shi, Y","Wang, N","Zou, Q M","32234130"],"abstract":["The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same beta-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated."],"journal":"Zhonghua Yu Fang Yi Xue Za Zhi","authors":["Shi, Y","Wang, N","Zou, Q M"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234130","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.3760/cma.j.cn112150-20200317-00366","keywords":["2019-ncov","animal models","vaccine"],"locations":["Moderna"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490273792000,"score":159.2379},{"pmid":32328406,"pmcid":"PMC7177048","title":"Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.","text":["Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.","The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and its impact on global health have made imperative the development of effective and safe vaccines for this lethal strain. SARS-CoV-2 now adds to the list of coronavirus diseases that have threatened global health, along with the SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) coronaviruses that emerged in 2002/2003 and 2012, respectively. As of April 2020, no vaccine is commercially available for these coronavirus strains. Nevertheless, the knowledge obtained from the vaccine development efforts for MERS and SARS can be of high value for COVID-19 (coronavirus disease 2019). Here, we review the past and ongoing vaccine development efforts for clinically relevant coronavirus strains with the intention that this information helps in the development of effective and safe vaccines for COVID-19. In addition, information from naturally exposed individuals and animal models to coronavirus strains is described for the same purpose of helping into the development of effective vaccines against COVID-19.","Infect Dis Ther","Padron-Regalado, Eriko","32328406"],"abstract":["The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and its impact on global health have made imperative the development of effective and safe vaccines for this lethal strain. SARS-CoV-2 now adds to the list of coronavirus diseases that have threatened global health, along with the SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) coronaviruses that emerged in 2002/2003 and 2012, respectively. As of April 2020, no vaccine is commercially available for these coronavirus strains. Nevertheless, the knowledge obtained from the vaccine development efforts for MERS and SARS can be of high value for COVID-19 (coronavirus disease 2019). Here, we review the past and ongoing vaccine development efforts for clinically relevant coronavirus strains with the intention that this information helps in the development of effective and safe vaccines for COVID-19. In addition, information from naturally exposed individuals and animal models to coronavirus strains is described for the same purpose of helping into the development of effective vaccines against COVID-19."],"journal":"Infect Dis Ther","authors":["Padron-Regalado, Eriko"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328406","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s40121-020-00300-x","keywords":["covid-19","coronavirus","mers","sars","vaccine"],"topics":["Treatment"],"weight":1,"_version_":1666138494558273536,"score":156.38531},{"pmid":32460358,"title":"The early landscape of COVID-19 vaccine development in the UK and rest of the world.","text":["The early landscape of COVID-19 vaccine development in the UK and rest of the world.","Since the first WHO notification on 31st December 2019, COVID-19, the respiratory disease caused by the coronavirus SARS-CoV-2, has been responsible for over 4 million confirmed infections, and almost 300,000 deaths worldwide. The pandemic has led to over half of the world's population living under lockdown conditions. To allow normal life to resume, public health interventions will be needed to prevent further waves of infections as lockdown measures are lifted. As one of the most effective countermeasures against infectious diseases, an efficacious vaccine is considered crucial to containing the COVID-19 pandemic. Following the publication of the genome sequence of SARS-CoV-2, vaccine development has accelerated at an unprecedented pace across the world. Here we review the different platforms employed to develop vaccines, the standard timelines of development and how they can be condensed in a pandemic situation. We focus on vaccine development in the UK and vaccines which have entered clinical trials around the world.","Immunology","Sharpe, Hannah R","Gilbride, Ciaran","Allen, Elizabeth","Belij-Rammerstorfer, Sandra","Bissett, Cameron","Ewer, Katie","Lambe, Teresa","32460358"],"abstract":["Since the first WHO notification on 31st December 2019, COVID-19, the respiratory disease caused by the coronavirus SARS-CoV-2, has been responsible for over 4 million confirmed infections, and almost 300,000 deaths worldwide. The pandemic has led to over half of the world's population living under lockdown conditions. To allow normal life to resume, public health interventions will be needed to prevent further waves of infections as lockdown measures are lifted. As one of the most effective countermeasures against infectious diseases, an efficacious vaccine is considered crucial to containing the COVID-19 pandemic. Following the publication of the genome sequence of SARS-CoV-2, vaccine development has accelerated at an unprecedented pace across the world. Here we review the different platforms employed to develop vaccines, the standard timelines of development and how they can be condensed in a pandemic situation. We focus on vaccine development in the UK and vaccines which have entered clinical trials around the world."],"journal":"Immunology","authors":["Sharpe, Hannah R","Gilbride, Ciaran","Allen, Elizabeth","Belij-Rammerstorfer, Sandra","Bissett, Cameron","Ewer, Katie","Lambe, Teresa"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460358","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/imm.13222","keywords":["covid-19","sars-cov-2","vaccine"],"locations":["GBR","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Treatment"],"weight":1,"_version_":1667967698967986176,"score":151.24223}]}